Asthma treatment during pregnancy is often shaped by a difficult calculation: patients and clinicians must weigh the risks of medication exposure against the dangers of uncontrolled respiratory disease. A nationwide cohort study published in JAMA Network Open offers reassuring evidence for one important part of that calculation, finding that continued use of inhaled corticosteroids, or ICS, during early pregnancy was not associated with increased risks of maternal or neonatal outcomes. The findings support current clinical recommendations that pregnant patients with asthma generally continue prescribed controller therapy rather than discontinue treatment because of concerns about fetal exposure.
Inhaled corticosteroids are the most widely recommended long-term controller medications for persistent asthma. They work primarily by reducing inflammation in the airways, limiting swelling, mucus production, and hypersensitivity to otherwise harmless triggers. Unlike systemic corticosteroids, which circulate throughout the body at substantially higher levels, inhaled medications are delivered directly to the lungs, where they exert their principal effect. Although a portion of each dose can enter the bloodstream, the overall systemic exposure is generally lower. This pharmacologic profile has made ICS therapy a central component of asthma management during pregnancy, when maintaining stable breathing is important for both the pregnant patient and the developing fetus.
The new analysis focused on ICS use during early pregnancy, a period that attracts particular concern because major fetal organs are forming. Medication exposures during the first trimester are therefore frequently scrutinized for possible associations with congenital abnormalities, pregnancy complications, or impaired fetal development. The researchers examined data from a nationwide cohort and compared pregnancy-related outcomes among individuals who continued ICS treatment with those who did not maintain therapy. According to the study summary, the analysis found no evidence that continued ICS use increased the risks assessed for mothers or newborns.
The result is significant because discontinuing asthma medication may appear intuitively safer to patients who are worried about exposing a fetus to drugs, but stopping treatment can allow airway inflammation to return. Asthma is not simply a condition of occasional breathlessness; persistent inflammation can narrow the airways and make them more reactive. Poorly controlled disease may lead to wheezing, reduced oxygenation, emergency treatment, or severe exacerbations requiring systemic corticosteroids and hospitalization. During pregnancy, serious respiratory deterioration can create risks that extend beyond the lungs, potentially affecting maternal health and the intrauterine environment. In that context, the safety question is not whether medication carries any exposure, but whether the benefits of preventing uncontrolled asthma outweigh potential treatment-related risks.
The study also draws attention to a recurring pattern in pregnancy care: frequent discontinuation of prescribed medication even when professional guidelines recommend continuation. Patients may stop ICS therapy after learning they are pregnant, reduce the dose without consulting a clinician, or use controller medication inconsistently because of fears about birth defects or other complications. Such decisions can be influenced by incomplete information, conflicting advice, or the mistaken belief that inhaled treatment is unnecessary when symptoms are temporarily mild. The researchers’ findings suggest that these concerns may contribute to avoidable treatment interruptions without providing a demonstrated safety benefit.
From a clinical perspective, the findings reinforce the principle that asthma control should be assessed individually throughout pregnancy. Continuing an ICS does not mean every patient should receive the same drug or dose. Treatment decisions depend on disease severity, symptom frequency, previous exacerbations, lung function, adherence, inhaler technique, and the specific medication prescribed. Clinicians may also consider whether a patient is using a controller consistently, whether rescue medication is needed more often, and whether environmental triggers are worsening symptoms. The study supports continuation of appropriate ICS therapy, but it does not eliminate the need for medical supervision or justify changing treatment without professional guidance.
The observational design is also important when interpreting the results. A cohort study can evaluate medication use and health outcomes across a large population and may identify associations that would be difficult to study in a randomized clinical trial, particularly when pregnancy is involved. However, observational research cannot establish with absolute certainty that treatment itself caused or prevented a particular outcome. People who continue their medication may differ from those who discontinue it in ways that are difficult to measure, including asthma severity, access to prenatal care, health literacy, smoking exposure, socioeconomic conditions, or adherence to other medical recommendations. Researchers can use statistical methods to account for measured differences, but some residual confounding may remain.
Even with those limitations, nationwide health data can provide a valuable view of real-world treatment patterns. Clinical trials involving pregnant patients are often restricted for ethical and practical reasons, leaving physicians dependent on registries, cohort studies, and postmarketing surveillance to evaluate medication safety. Large population-based analyses can help distinguish genuine signals from isolated reports and can offer evidence relevant to ordinary clinical practice. In this case, the absence of an observed increase in maternal or neonatal risks among patients who continued ICS therapy adds weight to existing guidance and may help reduce anxiety-driven discontinuation.
The researchers, led by Ju-Young Shin of Sungkyunkwan University and Yunha Noh of Chonnam National University in South Korea, emphasize that the results should be understood within a broader strategy of individualized risk assessment. The objective is not merely to avoid medication exposure, but to achieve the best possible balance between treatment benefits and potential harms. For a pregnant patient with asthma, that balance may favor continued ICS use because preventing exacerbations protects both the patient and fetus. Regular prenatal and asthma care, review of inhaler technique, monitoring of symptoms, and prompt attention to worsening breathing remain essential. The study’s central message is therefore practical as well as scientific: pregnancy should not automatically trigger withdrawal of effective asthma control therapy.
As asthma becomes increasingly recognized as a condition requiring continuous management rather than episodic symptom relief, evidence about medication safety during pregnancy has consequences beyond one treatment class. The new findings may reassure patients who have been advised to continue ICS therapy and provide clinicians with additional support when discussing the risks of stopping treatment. They also underline the importance of clear communication: the decision to continue or adjust an inhaled corticosteroid should be made with a qualified health professional, based on the patient’s clinical history and the need to maintain stable respiratory function. For now, the nationwide cohort evidence indicates that continued ICS use in early pregnancy was not linked to the adverse maternal or neonatal outcomes evaluated, supporting the recommendations already used in asthma care.
Subject of Research: Continued inhaled corticosteroid use during early pregnancy and associated maternal and neonatal outcomes in patients with asthma.
Web References: https://doi.org/10.1001/jamanetworkopen.2026.30781
References: Shin J-Y, Noh Y, et al. Study published in JAMA Network Open. DOI: 10.1001/jamanetworkopen.2026.30781.
Keywords: asthma, pregnancy, inhaled corticosteroids, ICS, maternal health, neonatal outcomes, medication safety, respiratory disease, cohort study, prenatal care
Tags: asthma control in pregnant womenAsthma management during pregnancyclinical guidelines for asthma in pregnancyeffects of inhaled steroids on fetal outcomesinhaled corticosteroids safetylong-term asthma controller medicationsmaternal and neonatal health with asthmamaternal-fetal health and respiratory diseasepharmacology of inhaled corticosteroidspregnancy and asthma treatmentrisks of asthma medication during pregnancysafety of inhaled corticosteroids in pregnancy
